Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology,Liver International

当前位置： X-MOL 学术 › Liver Int. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology
Liver International ( IF 6.0 ) Pub Date : 2021-06-26 , DOI: 10.1111/liv.14994
Peter R Galle ₁ , Masatoshi Kudo ₂ , Josep M Llovet _{3,

4,

5} , Richard S Finn ₆ , Mark Karwal ₇ , Denis Pezet ₈ , Tae-You Kim ₉ , Tsai-Sheng Yang ₁₀ , Sara Lonardi ₁₁ , Jiri Tomasek ₁₂ , Jean-Marc Phelip ₁₃ , Yann Touchefeu ₁₄ , Su-Jin Koh ₁₅ , Guido Stirnimann ₁₆ , Kun Liang ₁₇ , Kenyon D Ogburn ₁₇ , Chunxiao Wang ₁₇ , Paolo Abada ₁₇ , Ryan C Widau ₁₇ , Andrew X Zhu _{18,

19}

Affiliation

Department of Internal Medicine, Mainz University Medical Center, Mainz, Germany.
Departments of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain.
Institució Catalana d'Estudis Avançats (ICREA), Barcelona, Spain.
University of California, Los Angeles, CA, USA.
University of Iowa Hospitals and Clinics, University of Iowa Health Care, Iowa City, IA, USA.
Estaing Hospital, Aubrac, Clermont-Ferrand, France.
Seoul National University Hospital, Seoul, Korea.
Chang Gung Memorial Hospital, Taoyuan, China.
Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Masaryk Memorial Cancer Institute, Masaryk University, Brno, Czech Republic.
University Hospital Saint-Etienne North, Saint Etienne, France.
CHU Hôtel-Dieu, Nantes, France.
Division of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
University Hospital Inselspital and University of Bern, Bern, Switzerland.
Eli Lilly and Company, Indianapolis, IN, USA.
Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Jiahui International Cancer Center, Jiahui Health, Shanghai, China.

Hepatocellular carcinoma (HCC) is a common complication of chronic liver disease with diverse underlying aetiologies. REACH/REACH-2 were global phase III studies investigating ramucirumab in advanced HCC (aHCC) following sorafenib treatment. We performed an exploratory analysis of outcomes by liver disease aetiology and baseline serum viral load.

中文翻译：

雷莫芦单抗治疗既往接受过治疗的晚期肝细胞癌患者：肝病病因学的影响

肝细胞癌（HCC）是慢性肝病的常见并发症，其潜在病因多种多样。 REACH/REACH-2 是全球 III 期研究，调查索拉非尼治疗后的晚期 HCC (aHCC) 中的雷莫芦单抗。我们对肝病病因学和基线血清病毒载量的结果进行了探索性分析。

更新日期：2021-06-26

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11